ViiV Healthcare Advances Twice-Yearly HIV Treatments with VH184 and VH499
Event summary
- ViiV Healthcare presented phase 1 data for VH184, a third-generation INSTI, showing potential for twice-yearly dosing with a single injection.
- VH184 demonstrated improved resistance profile compared to bictegravir in resistant HIV strains.
- VH499, an investigational capsid inhibitor, showed potential for ultra long-acting (ULA) twice-yearly dosing and was generally well tolerated.
- Both VH184 and VH499 were presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026).
The big picture
ViiV Healthcare's focus on long-acting HIV therapies aligns with broader industry trends toward reducing treatment burden and improving adherence. The company's pipeline advancements could reshape HIV care by offering less frequent dosing options, potentially capturing a significant share of the $25 billion global HIV market. The strategic shift toward ultra long-acting treatments also positions ViiV Healthcare to address evolving patient preferences and resistance challenges.
What we're watching
- Clinical Progress
- The pace at which VH184 and VH499 advance through phase 2b studies will determine their viability as twice-yearly treatments.
- Market Differentiation
- Whether ViiV Healthcare can sustain a competitive edge with its long-acting therapies in a crowded HIV treatment market.
- Regulatory Pathway
- How regulatory agencies will evaluate the safety and efficacy of ultra long-acting HIV treatments for approval.
Related topics